Information Provided By: 
Fly News Breaks for May 19, 2017
SHPG
May 19, 2017 | 05:49 EDT
HSBC analyst Steve McGarry downgraded Shire to Reduce saying that while the hereditary angioedema data are positive, invesotrs should avoid the "hemophilia risk." The analyst believes the Baxalta deal could hurt return on invested capital if competition in hemophilia "gets notably more severe." He lowered his price target for Shire shares to 4,450p from 4,550p.
News For SHPG From the Last 2 Days
There are no results for your query SHPG
